![Chiral N-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof](/docs/US/2018-09-04/US10065961B2/abs.jpg.600x600.jpg)
- Patent Title: Chiral N-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof
-
Application No.: US15259922Application Date: 2016-09-08
-
Publication No.: US10065961B2Publication Date: 2018-09-04
- Inventor: Hamid R. Hoveyda , Guillaume Dutheuil , Graeme L. Fraser , Marie-Odile Roy , Mohamed E. Bousmaqui , Frederic Batt
- Applicant: Euroscreen S.A.
- Applicant Address: BE Gosselies
- Assignee: Ogeda SA.
- Current Assignee: Ogeda SA.
- Current Assignee Address: BE Gosselies
- Agency: Locke Lord LLP
- Agent Nicholas J. DiCeglie, Jr.
- Priority: EP11183678 20111003; EP11183679 20111003; EP11183681 20111003; EP11183692 20111003
- Main IPC: C07D487/04
- IPC: C07D487/04 ; C07D241/38
![Chiral N-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof](/abs-image/US/2018/09/04/US10065961B2/abs.jpg.150x150.jpg)
Abstract:
The present invention relates to novel compounds of Formula I and their use in therapeutic treatments. The invention further relates to a novel chiral synthesis of 5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines using N-sp3 protective groups. The invention also provides intermediates for use in the synthesis of compounds of Formula I.
Public/Granted literature
Information query
